Question normal

Dr. Plutzky is our lead moderator for the papers on the reduction in cardiovascular outcomes associated with newer antidiabetes drugs. (Cardiovascular Outcomes with Newer Antidiabetes Drugs). This has been a topic of hot debate for several years, but this new data seems more definitive. Should we be prescribing these drugs with this benefit in mind? Dr. Plutzky will continue this discussion -- all are welcome to ask, answer, respond, and follow-up.